Literature DB >> 15001119

Pathogenesis of retinopathy of prematurity.

Lois E H Smith1.   

Abstract

Retinopathy of prematurity (ROP) is a major cause of blindness in children in developed countries. ROP, a two-phase disease, is initiated with delayed retinal vascular growth after premature birth (phase I). Insufficient vascularization of the developing retina creates hypoxia, which precipitates the release of factors stimulating new and abnormal blood vessel growth (phase II). ROP develops because of abnormalities in both oxygen-regulated and non-oxygen-regulated factors, which affect both phases of the disease. Vascular endothelial growth factor (VEGF) is an important oxygen-regulated factor that, if suppressed, inhibits normal vessel growth, but in excess, precipitates retinal neovascularization. A critical non-oxygen-regulated growth factor is insulin-like growth factor (IGF-1). Similar to VEGF, low levels of IGF-1 prevent normal vessel growth (phase I), and higher levels allow neovascularization (phase II). We found that premature infants who develop ROP have low levels of serum IGF-1 compared with age-matched infants without disease. IGF-1 is critical to normal vascular development. Low IGF-1 predicts ROP, and restoration of IGF-1 to normal levels might prevent ROP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15001119     DOI: 10.1016/S1084-2756(03)00119-2

Source DB:  PubMed          Journal:  Semin Neonatol        ISSN: 1084-2756


  47 in total

Review 1.  Preterm birth and neurodevelopmental outcome: a review.

Authors:  Carla Arpino; Eliana Compagnone; Maria L Montanaro; Denise Cacciatore; Angela De Luca; Angelica Cerulli; Stefano Di Girolamo; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-03-27       Impact factor: 1.475

2.  Neonatal Intermittent Hypoxia, Reactive Oxygen Species, and Oxygen-Induced Retinopathy.

Authors:  Kay D Beharry; Charles L Cai; Gloria B Valencia; Arwin M Valencia; Douglas R Lazzaro; Fayez Bany-Mohammed; Jacob V Aranda
Journal:  React Oxyg Species (Apex)       Date:  2017-01

3.  Identification of a novel inhibitor of the canonical Wnt pathway.

Authors:  Kyoungmin Park; Kyungwon Lee; Bin Zhang; Ti Zhou; Xi He; Guoquan Gao; Anne R Murray; Jian-Xing Ma
Journal:  Mol Cell Biol       Date:  2011-05-16       Impact factor: 4.272

4.  Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy.

Authors:  Mohamed Al-Shabrawey; Manuela Bartoli; Azza B El-Remessy; Daniel H Platt; Sue Matragoon; M Ali Behzadian; Robert W Caldwell; Ruth B Caldwell
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 5.  VEGF in Signaling and Disease: Beyond Discovery and Development.

Authors:  Rajendra S Apte; Daniel S Chen; Napoleone Ferrara
Journal:  Cell       Date:  2019-03-07       Impact factor: 41.582

6.  Connective tissue growth factor as a mediator of intraocular fibrosis.

Authors:  Shikun He; Youxin Chen; Rima Khankan; Ernesto Barron; Richard Burton; Danhong Zhu; Stephen J Ryan; Noelynn Oliver; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

7.  Plus Disease: Why is it Important in Retinopathy of Prematurity?

Authors:  Carlos E Solarte; Abdulaziz H Awad; Clare M Wilson; Anna Ells
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

8.  Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage.

Authors:  Kyoungmin Park; Ying Chen; Yang Hu; Aaron S Mayo; Uday B Kompella; Richard Longeras; Jian-xing Ma
Journal:  Diabetes       Date:  2009-06-02       Impact factor: 9.461

Review 9.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

10.  [Pathogenesis of retinopathy of prematurity].

Authors:  A Stahl; W A Lagrèze; H T Agostini
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.